Carregando…
Orthofix Medical Inc.
Como a empresa evoluiu, ano a ano. Receita e dívida vêm dos relatórios anuais — na maioria das empresas, os 10-K entregues à SEC desde 2009; os dividendos, dos próprios pagamentos.
As barras são um saldo na data de fechamento; as linhas são o que aconteceu ao longo do ano. Receita acima do patrimônio é o normal, não anomalia — significa que a empresa gira o capital mais de uma vez por ano.
Grandes gestores que reportaram esta ação no 13F mais recente.
Nenhum dos investidores acompanhados reportou posição em OFIX.
▼ -73.8% em 5A.
hoje você teria $247.64▼ -75.2%
Com dividendos reinvestidos e desdobramentos considerados. Preço passado diz o que aconteceu, não o que vai acontecer.
Os últimos 17 anos fechados. Cada múltiplo usa o preço de fechamento daquele ano e os números reportados naquele ano — não os de hoje. O alcance é o dos relatórios anuais que temos.
| Indicador | Mediana | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Preço no fim do ano | $15.16 | $17.46 | $13.48 | $20.53 | $31.09 | $42.98 | $46.18 | $52.49 | $54.70 | $36.18 | $39.21 | $30.06 | $22.82 | $39.33 | $35.23 | $29.00 | $30.93 |
Empresas de tamanho parecido em Healthcare, para comparar. As colunas são as mesmas de cima, na mesma ordem.
| Ação | Preço | P/L | P/VP | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| LRMRLarimar Therapeutics, Inc. | $3.82 | — | 3.1x | — | -139.63% | $396.83M |
| MYGNMyriad Genetics Inc | $4.17 | — | 1.3x | — | -32.54% | $398.86M |
| XFORX4 Pharmaceuticals, Inc | $4.04 | 2.9x | 2.5x | — | -113.08% | $400.55M |
| AUNAAUNA S.a | $5.18 |
Orthofix Medical Inc., together with its subsidiaries, operates as a medical technology company in the United States, Italy, the United Kingdom, France, Germany, Brazil, and internationally. It operates through two segments, Global Spine and Global Limb Reconstruction. The Global Spine segment manufactures, distributes, and provides support services for bone growth stimulation devices that enhance bone fusion; designs, develops, and markets a portfolio of spine fixation implant products for use throughout the spinal column; and offers bone graft substitutes, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers in various forms with supporting graft delivery solutions to treat various spinal, orthopedic, and dental conditions. This segment also designs, develops, and markets a portfolio of navigation technologies, including tracked surgical tools, intelligent software, and imaging equipment based on machine-vision and optical innovations; and 7D FLASH Navigation System, a navigation platform for spinal and cranial procedures. The Global Limb Reconstruction segment offers products and solutions for the underserved limb reconstruction market, including deformity correction, limb lengthening, complex fracture management, and limb preservation. This segment also designs, develops, and markets external and internal fixation limb reconstruction products that are coupled with enabling digital technologies to support the entire patient care continuum. It sells its products through distributors and sales representatives to hospitals, healthcare organizations, healthcare providers, ambulatory surgery centers, and out-patient hospitals. The company was formerly known as Orthofix International N.V. and changed its name to Orthofix Medical Inc. in July 2018. Orthofix Medical Inc. was founded in 1980 and is headquartered in Lewisville, Texas.
Descrição da empresa fornecida pelo Yahoo Finance. A descrição é publicada pela fonte apenas em inglês.
| P/L | 21.8x | — | — | — | — | — | 330.6x | — | 72.9x | 160.9x | 212.8x | — | — | — | 17.8x | — | 11.7x | 21.8x |
| P/Receita | 1.5x | 0.7x | 0.9x | 0.7x | 1.6x | 1.3x | 2.1x | 1.9x | 2.2x | 2.3x | 1.6x | 1.8x | 1.4x | 1.0x | 1.7x | 1.5x | 1.1x | 1.0x |
| P/VP | 2.2x | 1.4x | 1.4x | 0.8x | 2.2x | 1.8x | 2.4x | 2.7x | 3.0x | 3.4x | 2.5x | 2.5x | 1.9x | 1.4x | 2.1x | 2.4x | 1.7x | 2.2x |
| EPS | -$2.33 | -$3.30 | -$4.12 | -$0.98 | -$1.95 | $0.13 | -$1.51 | $0.72 | $0.34 | $0.17 | -$0.15 | -$0.46 | -$1.54 | $2.21 | -$0.97 | $2.47 | $1.42 |
| Margem líquida | -2.12% | -11.21% | -15.76% | -20.28% | -4.29% | -8.26% | 0.62% | -6.19% | 3.05% | 1.43% | 0.75% | -0.71% | -2.12% | -7.25% | 9.73% | -4.06% | 9.58% | 4.49% |
| ROE | -2.85% | -20.49% | -25.04% | -25.29% | -5.86% | -11.39% | 0.71% | -8.69% | 4.12% | 2.10% | 1.16% | -0.97% | -2.85% | -9.74% | 12.02% | -6.31% | 14.72% | 10.19% |
Mediana, e não média: um único ano de lucro quase zero dá P/L de 400 e arrastaria a média sozinho. Anos com P/L acima de 200x ficam de fora, o mesmo corte do preço justo — por isso esta mediana bate com o método “histórico da própria empresa” abaixo. Preço e LPA não têm mediana: são séries que crescem.
| 86.3x |
| 0.7x |
| — |
| 1.62% |
| $383.61M |
| TKNOAlpha Teknova, Inc. | $7.12 | — | 5.5x | — | -24.19% | $382.26M |
| RLMDRelmada Therapeutics Inc | $3.78 | — | 0.4x | — | -55.66% | $403.21M |